How to Develop and Implement a National Drug Policy (Second Edition)
(2001; 96 pages) [French] [Spanish] View the PDF document
Table of Contents
View the documentContributors
View the documentAbbreviations and acronyms
View the documentPreface
Open this folder and view contentsPart I: How to develop and implement a national drug policy
Close this folderPart II: Key components of a national drug policy
Open this folder and view contents4. Selection of essential drugs
Open this folder and view contents5. Affordability
Open this folder and view contents6. Drug financing
Open this folder and view contents7. Supply systems
Close this folder8. Drug regulation
View the document8.1 Need for drug regulation and quality assurance
View the document8.2 Basic requirements for drug regulation
View the document8.3 Core elements of drug regulation
View the document8.4 Stepwise approach to drug registration
View the document8.5 Quality
View the document8.6 Safety
View the document8.7 Efficacy
View the document8.8 Information and drug promotion
View the document8.9 Information exchange with WHO and with other agencies
Open this folder and view contents9. Rational use of drugs
Open this folder and view contents10. Research
Open this folder and view contents11. Human resources development
Open this folder and view contents12. Monitoring and evaluation
View the documentReferences
View the documentSelected WHO publications and documents of related interest
View the documentBack cover
 

8.8 Information and drug promotion

A medicine is a chemical product plus information. It is a very important task of the regulatory agency to ensure that drug information is unbiased, correct, updated and easily accessible to prescribers and consumers.

Review and approval of product data sheets and labels

The system of drug evaluation and registration includes the review and approval of the product data sheets and labels. This information is usually disseminated through drug inserts or drug formularies. There is increasing discussion of whether the information that the DRA uses to assess the efficacy and safety of new drugs for market approval should be made accessible to public scrutiny - even if the information is unpublished data which the company may consider as confidential. Many provincial and institutional drug committees would like to use this information for their own decisions on clinical guidelines and essential drugs lists.

Drug promotion

Regulations to control drug promotion and to ensure the quality of information provided are important in promoting more rational use of medicines. National drug policies should therefore include provisions for regulating promotional activities. WHO’s Ethical criteria for medicinal drug promotion58 can serve as a basis for developing measures to control drug promotion. The guiding principles are that promotion should be in keeping with national health policies and in compliance with national regulations, as well as meeting voluntary standards where they exist. All promotion-making claims should be reliable, accurate, truthful, informative, balanced, up-to-date, capable of substantiation and in good taste.

Monitoring the quality of promotional activities needs adequate resources and a clear political commitment to enforce the relevant regulations. Possible sanctions include appropriate fines and published retractions of misleading claims in the media in which they were originally made.

to previous section
to next section
 
 
The WHO Essential Medicines and Health Products Information Portal was designed and is maintained by Human Info NGO. Last updated: August 29, 2014